Student or educator? Sign up with your school email and get 6 months of Pro free.
Cited by 232

The DOI matches its Crossref record.

68Ga-DOTANOC PET/CT Clinical Impact in Patients with Neuroendocrine Tumors

Open access
Ambrosini, Valentina, Campana, Davide, Bodei, Lisa, Nanni, Cristina, Castellucci, Paolo, Allegri, Vincenzo, Montini, Gian Carlo, Tomassetti, Paola, Paganelli, Giovanni, Fanti, Stefano · 2010 · Journal of Nuclear Medicine

Abstract

UNLABELLED: Several authors reported the superiority of (68)Ga-DOTANOC PET/CT to conventional imaging (CI) for the assessment of neuroendocrine tumors (NET). However, the detection of a higher number of lesions is not necessarily followed by a modification of disease stage or therapeutic approach. The aim of this study was to assess the impact of (68)Ga-DOTANOC PET/CT on the clinical management of NET patients. METHODS: The study included 90 patients with pathologic confirmation of NET, CT performed within a month of (68)Ga-DOTANOC PET/CT, and a follow-up period of at least 1 y. PET/CT results were compared with CI results. As a standard of reference to finally evaluate PET results, clinical and imaging follow-up data were used. To assess the clinical impact of PET findings, all referring physicians were contacted after PET and asked about how patients were managed. Stage or therapy modifications were independently recorded, and the overall impact was evaluated patient by patient if PET results either affected therapy or caused a change in disease stage. RESULTS: Considering PET/CT and CI concordant cases (47/90 [52.2%]), PET findings affected the therapeutic management in 17 of 47 (36.2%) patients. Although PET did not result in modification of disease stage, (68)Ga-DOTANOC detected a higher lesion number in most patients. PET/CT and CI findings were discordant in 42 of 90 (46.7%) patients: PET resulted in a modification of stage in 12 patients (28.6%) and affected the treatment plan in 32 patients (76.2%). PET and CT were both equivocal in 1 patient (1/90). Considering all cases, (68)Ga-DOTANOC PET/CT affected either stage or therapy in 50 of 90 (55.5%) patients. The most frequent impact on management (27 patients) was the initiation or continuance of peptide receptor radionuclide therapy, followed by the initiation or continuance of somatostatin analog medical treatment (7 patients) and referral to surgery (6 patients). PET prevented unnecessary surgery in 6 patients and excluded from treatment with somatostatin analogs 2 patients with NET lesions that did not express somatostatin receptors. Less frequent impacts on management included the initiation of radiotherapy (1 patient), further diagnostic investigation (1 patient), and liver transplantation (1 patient). CONCLUSION: (68)Ga-DOTANOC PET/CT either affected stage or caused a therapy modification in more than half the patients, thus confirming the clinical role of PET in the management of NET.

Overview

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.2967/jnumed.109.071712

Cites

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cited by

See all 232

Metadata

Authors
Ambrosini, V., Campana, D., Bodei, L., Nanni, C., Castellucci, P., Allegri, V., Montini, G. C., Tomassetti, P., Paganelli, G., & Fanti, S.
Venue
Journal of Nuclear Medicine
Published
2010-04-15
Volume
51
Issue
5
Pages
669-673
ISSN
  • 0161-5505 (ISSN-L)
  • 2159-662X
OpenAlex
W2162735572
Cited by
232
References
0
FWCI
16.77
Type
journal article
Language
en
Open access
bronze

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: 68Ga-DOTANOC PET/CT Clinical Impact in Patients with Neuroendocrine Tumors. https://app.cochat.ai/papers/10.2967/jnumed.109.071712
The paper
Ambrosini, V., Campana, D., Bodei, L., Nanni, C., Castellucci, P., Allegri, V., Montini, G. C., Tomassetti, P., Paganelli, G., & Fanti, S. (2010). 68Ga-DOTANOC PET/CT Clinical Impact in Patients with Neuroendocrine Tumors. Journal of Nuclear Medicine. https://doi.org/10.2967/jnumed.109.071712

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.